ArticleJournal of virology2022
WTAP Targets the METTL3 m
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- m6A epigenetic modification of viral RNA is critical for the transmission cycle of mosquito-borne flaviviruses.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- m6A-Modified Nucleotide Bases Improve Translation of In Vitro-Transcribed Chimeric Antigen Receptor (CAR) mRNA in T Cells.International journal of molecular sciences · 2026Article
- IGF2BP3-STAT3-METTL3 axis promotes malignant progression in hepatocellular carcinoma (HCC).Human genomics · 2025Article
- Regulation of viral hepatitis by N6-methyladenosine RNA methylation.Emerging microbes & infections · 2025Review
- Investigation of a squaramide motif as a bioisostere of the amino-acid group of S-adenosyl-L-methionine and its functional impact on RNA methylation.Communications chemistry · 2025Article
- Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.Cancer cell international · 2025Review
- Crosstalk Between N6-Methyladenosine and Other Epigenetic Mechanisms in Central Nervous System Development and Disorders.Biomolecules · 2025Review
- Targeting G9a-miScience · 2025Article
- Strain-Divergent m6A Landscapes Modulate Nipah Virus Replication and METTL3 Inhibition Attenuates Virulence.Viruses · 2025Article
- Insights into the role of N6-methyladenosine (m6A) in plant-virus interactions.Journal of virology · 2025Review
- Unveiling the dynamics and therapeutic potential of mInternational journal of biological sciences · 2025Review
- RNA Modifications in Pathogenic Viruses: Existence, Mechanism, and Impacts.Microorganisms · 2024Review
- Recent insights into NCurrent opinion in genetics & development · 2024Review
- Challenges to mapping and defining mRNA (New York, N.Y.) · 2024Article
- NNature communications · 2024Article
- Classical swine fever virus non-structural protein 5B hijacks host METTL14-mediated m6A modification to counteract host antiviral immune response.PLoS pathogens · 2024Article
- A bibliometric analysis of m6A methylation in viral infection from 2000 to 2022.Virology journal · 2024Article
- Modifying the antiviral innate immune response by selective writing, erasing, and reading of mCell chemical biology · 2024Review
- The N6-methyladenosine RNA epigenetic modification modulates the amplification of coxsackievirus B1 in human pancreatic beta cells.Frontiers in microbiology · 2024Article
- Interconnections between mLife science alliance · 2024Review
Corrections and comments
- Update of
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Modification of the hepatitis C virus (HCV) positive-strand RNA genome by N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.